Published in Nat Rev Cancer on August 23, 2016
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | NCT01475058
Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | NCT01722149
Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas | NCT01723306
Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer | NCT01897415
CD19 Redirected Autologous T Cells | NCT01747486
CART-meso in Mesothelin Expressing Cancers | NCT02159716
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | NCT02280811
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies | NCT01697527
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | NCT01621724
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | NCT02203825
A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | NCT02349724
cMet CAR RNA T Cells Targeting Breast Cancer | NCT01837602
CT Antigen TCR-Engineered T Cells for Myeloma | NCT01892293
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | NCT02465983
CD19 Redirected Autologous T Cells for Hodgkin Lymphoma | NCT02277522
CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR | NCT02331693
CART-19 Immunotherapy in Mantle Cell Lymphoma | NCT02081937
CD123 Redirected Autologous T Cells for AML | NCT02623582
Anti-GPC3 CAR T for Treating Patients With Advanced HCC | NCT02395250
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients | NCT01586403
Investigator Initiated Phase 1 Study of TBI-1201 | NCT02096614
CART-BCMA Cells for Multiple Myeloma | NCT02546167
A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy (CD19) | NCT01493453
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor | NCT02617134
CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) | NCT02274584
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients | NCT02228096
Investigator Initiated Phase 1 Study of TBI-1301 | NCT02366546
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET) | NCT02445248
Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL | NCT02546739
CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy | NCT02537977
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | NCT02550535
Study With T-cel Receptor Gene Therapy in Metastatic Melanoma (TCR) | NCT02654821
CD19+ CAR T Cells for Lymphoid Malignancies | NCT02529813
CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies | NCT02443831
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
Driving gene-engineered T cell immunotherapy of cancer. Cell Res (2016) 0.89
NK cells converge lytic granules to promote cytotoxicity and prevent bystander killing. J Cell Biol (2016) 0.81
Reconstructing the immune system with lentiviral vectors. Virus Genes (2017) 0.81
Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol (2017) 0.78
Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells. Mol Ther Methods Clin Dev (2017) 0.76
Diacylglycerol Kinases in T Cell Tolerance and Effector Function. Front Cell Dev Biol (2016) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy. Transl Res (2017) 0.76
Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer? Mol Ther (2017) 0.75
Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs. Mol Ther Methods Clin Dev (2017) 0.75
Molecular imaging biomarkers for cell-based immunotherapies. J Transl Med (2017) 0.75
The best spot to park a CAR. Nat Biotechnol (2017) 0.75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol (2017) 0.75
Engineering HIV-Specific Immunity with Chimeric Antigen Receptors. AIDS Patient Care STDS (2016) 0.75
DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy. Front Cell Dev Biol (2017) 0.75
Cytotoxic CD4 T Cells: Differentiation, Function, and Application to Dengue Virus Infection. Front Immunol (2016) 0.75
Transcriptional and epigenetic regulation of T cell hyporesponsiveness. J Leukoc Biol (2017) 0.75
DlgR2 knockdown boosts dendritic cell activity and inhibits hepatocellular carcinoma tumor in-situ growth. Oncotarget (2017) 0.75
Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). Transl Lung Cancer Res (2017) 0.75
The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. Oncoimmunology (2017) 0.75
Reprogramming cellular functions with engineered membrane proteins. Curr Opin Biotechnol (2017) 0.75
Tumor location impacts immune response in mouse models of colon cancer. Oncotarget (2017) 0.75
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Commun (2017) 0.75
Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors. Cell Rep (2017) 0.75
Creating a Homeodomain with High Stability and DNA Binding Affinity by Sequence Averaging. J Am Chem Soc (2017) 0.75
Mitochondrial Priming by CD28. Cell (2017) 0.75
Manufacturing Cell Therapies Using Engineered Biomaterials. Trends Biotechnol (2017) 0.75
Ionic CD3-Lck interaction regulates the initiation of T-cell receptor signaling. Proc Natl Acad Sci U S A (2017) 0.75
Mitochondrial control of immunity: beyond ATP. Nat Rev Immunol (2017) 0.75
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol (2017) 0.75
Tumor-specific hepatic stellate cells (tHSCs) induces DIgR2 expression in dendritic cells to inhibit T cells. Oncotarget (2017) 0.75
Accelerating Patients' Access to Advanced Therapies in the EU. Mol Ther Methods Clin Dev (2017) 0.75
A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Mol Ther (2017) 0.75
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell (1991) 6.13
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Lond B Biol Sci (1954) 5.72
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2014) 5.42
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta (1994) 4.92
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A (1989) 4.63
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 4.58
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med (2004) 4.41
Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene (2004) 4.29
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant (2010) 3.79
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem (2003) 3.30
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest (2003) 2.87
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77
State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet (2011) 2.71
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol (2012) 2.70
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol (2006) 2.70
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell (2012) 2.69
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Mesothelin targeted cancer immunotherapy. Eur J Cancer (2007) 2.54
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol (2003) 2.51
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer (1992) 2.50
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science (2015) 2.50
Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol (2004) 2.49
Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell (1991) 2.45
T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci U S A (1991) 2.32
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov (2015) 2.29
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2.25
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther (2007) 2.23
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol (2004) 2.22
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol (2005) 2.21
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med (2015) 2.20
APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol (2000) 2.19
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood (2011) 2.15
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood (2003) 2.12
Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol (2003) 2.12
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol (2015) 2.11
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res (1984) 2.01
Immune regulation of cancer. J Clin Oncol (2010) 1.99
The basic biology of HER2. Ann Oncol (2001) 1.97
Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol (1998) 1.96
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res (2008) 1.95
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med (2015) 1.91
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell (2016) 1.82
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest (2016) 1.75
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 1.75
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol (2012) 1.71
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood (2016) 1.69
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res (1987) 1.68